CNBX · CIK 0001343009
CNBX PHARMACEUTICALS INC.
Annual figures as reported, FY2014–FY2025. Ratios and growth rates derived on-page.
Pharmaceutical Preparations
Company profile
Revenue
$0
▼ −100.0% vs FY2024
Net income
−$314K
▲ +54.8% vs FY2024
Operating cash flow
−$171K
▲ +29.9% vs FY2024
Diluted EPS
$0.00
▲ +100.0% vs FY2024
Revenue
Annual, as reported
Net income
Losses shown in terracotta
Recent quarters
momentum · last 12 quartersRevenue — May ’26 quarter
$0
Net income — May ’26 quarter
−$154K
▼ −158.1% vs May ’25
Revenue — trailing 12 months
$0
Diluted EPS — trailing 12 months
$0.00
▲ +120.0% vs May ’25
Quarterly revenue
Discrete quarters; Q4 derived from the annual figure
Quarterly net income
Losses shown in terracotta
| Quarter | Revenue | Rev. YoY | Gross margin | Net income | Net margin | Diluted EPS |
|---|---|---|---|---|---|---|
| May ’26 | $0 | — | — | −$154K | — | $0.00 |
| Feb ’26 | $0 | — | — | −$44K | — | $0.00 |
| Nov ’25 | $0 | — | — | −$114K | — | $0.00 |
| Aug ’25 | $0 | — | — | −$150K | — | $0.00 |
| May ’25 | $0 | — | — | −$60K | — | $0.00 |
| Feb ’25 | $0 | −100.0% | — | −$70K | — | $0.00 |
| Nov ’24 | $0 | −100.0% | — | −$34K | — | −$0.00 |
| Aug ’24 | $0 | −100.0% | — | −$61K | — | −$0.00 |
Profitability & returns
quality of earningsMargins
Share of revenue kept at each line
Operating marginNet margin
Returns on capital
Net income vs year-end equity and assets
Return on equityReturn on assets
Cash flow
cash generationOperating cash flow
Net cash from operations
Shareholder returns
capital allocationDiluted shares outstanding
Falling count means buybacks outpace dilution
Balance sheet
financial positionStockholders’ equity
At fiscal year end
Key ratios
derived per fiscal year| Fiscal year | Op. margin | Net margin | ROE | ROA | Current ratio |
|---|---|---|---|---|---|
| FY2025 | — | — | — | −1703.0% | 0.01× |
| FY2024 | −448.3% | −534.5% | — | −2215.2% | 0.01× |
| FY2023 | −227.1% | −904.6% | — | −743.5% | 0.09× |
| FY2022 | −9860.4% | −12428.2% | −228.1% | −459.0% | 0.08× |
| FY2021 | — | — | −176.9% | −103.8% | 1.25× |
| FY2020 | −42524.1% | −104337.9% | −423.2% | −336.5% | 2.04× |
| FY2019 | −33563.0% | 11510.4% | 7.7% | 7.5% | 9.81× |
| FY2018 | −39670.1% | −39335.7% | −142.8% | −118.6% | 3.01× |
| FY2017 | −32616.1% | −34022.5% | — | −53.2% | 5.03× |
| FY2016 | −249.5% | −273.0% | — | −1295.2% | 0.04× |
| FY2015 | — | — | — | −1886.1% | 0.08× |
| FY2014 | — | — | −673.6% | −236.4% | 1.52× |
Annual figures
as reported| Fiscal year | Revenue | Gross profit | Op. income | Net income | Diluted EPS | Op. cash flow | Capex | Total assets | Liabilities | Equity | Cash | LT debt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 | $0 | — | −$272K | −$314K | $0.00 | −$171K | — | $18K | $2.5M | −$2.5M | $15K | — |
| FY2024 | $130K | — | −$583K | −$695K | −$0.02 | −$244K | — | $31K | $2.5M | −$2.5M | $26K | — |
| FY2023 | $410K | — | −$931K | −$3.7M | −$0.42 | −$113K | — | $499K | $2.5M | −$2.0M | $130K | — |
| FY2022 | $30K | — | −$3.0M | −$3.7M | −$3.59 | −$1.7M | — | $811K | −$821K | $1.6M | $118K | — |
| FY2021 | $0 | — | −$2.6M | −$3.2M | −$0.02 | −$2.5M | — | $3.1M | $1.3M | $1.8M | $1.4M | — |
| FY2020 | $7K | — | −$3.0M | −$7.5M | −$0.10 | −$2.8M | — | $2.2M | $455K | $1.8M | $778K | — |
| FY2019 | $10K | — | −$3.3M | $1.1M | $0.02 | −$3.1M | — | $15.2M | $439K | $14.7M | $266K | — |
| FY2018 | $10K | — | −$3.8M | −$3.8M | −$0.03 | −$2.0M | — | $3.2M | $539K | $2.6M | $1.4M | — |
| FY2017 | $6K | — | −$1.9M | −$1.9M | −$0.02 | −$864K | — | $3.6M | $6.6M | −$2.9M | $1.4M | — |
| FY2016 | $113K | — | −$281K | −$307K | $0.00 | −$120K | — | $24K | $491K | −$467K | $19K | — |
| FY2015 | $0 | — | −$537K | −$541K | −$0.01 | −$179K | — | $29K | $338K | −$310K | $25K | — |
| FY2014 | — | — | −$216K | −$270K | −$0.01 | −$195K | — | $114K | $74K | $40K | $99K | — |
Latest filings
the most recent regulatory filings10-QFORM 10-Q FOR MAY 20262026-06-24 ↗SCHEDULE 13G/ASEC filing2026-05-08 ↗10-QQuarterly report2026-04-14 ↗8-KCurrent report — material event2026-03-17 ↗SCHEDULE 13G/ASEC filing2026-02-05 ↗10-QQUARTERLY REPORT2026-01-14 ↗10-KFORM 10-K FOR AUG 20252025-12-01 ↗SCHEDULE 13G/ASEC filing2025-11-10 ↗SCHEDULE 13G/ASEC filing2025-08-13 ↗10-QQuarterly report2025-07-14 ↗
Company logos by Elbstream and unavatar.
All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.